Rating: Neutral | Target Price: RMB 155–195 (base-case fair value range) | Current Price: RMB 168.28 (close on 2026-10-30) | Margin of Safety: approx. -7.9% (base-case fair value lower bound below current price; no substantive margin of safety) | Time Horizon: 6–12 months
Market Cap: RMB 108.36 billion | Total Shares: 643.94 million | PE-TTM: 48.6x | 2026E PE: 42–44x | 2027E PE: 31–33x
Changchuan Technology is a platform-level leader in domestic semiconductor back-end test equipment, currently in an earnings explosion phase driven jointly by AI test demand and domestic substitution: revenue for the first three quarters of 2026 was RMB 5.942 billion (+57.25%), net profit attributable to shareholders was RMB 1.765 billion (+103.92%), and Q3 standalone net profit of RMB 801 million hit a record high. On the industry side, per SEMI, the global test equipment market grew 55.3% in 2025 and is expected to grow another 31% in 2026 — the fastest-growing segment within semiconductor equipment. However, this report's conclusion is a restrained Neutral: the current price of RMB 168.28 already fairly prices the base-case path of "two years of high growth delivered + 2027 growth step-down" — the base-case fair value range is RMB 155–195, with a probability-weighted fair value of approx. RMB 173, only about 3% above the current price; the odds are roughly symmetric (downside to bear-case midpoint approx. -55%, upside to bull-case midpoint approx. +59%), with no substantive margin of safety. Profit quality is weaker than it appears (inventory of RMB 6.180 billion is approx. 78% of annualized revenue; R&D capitalization rate 26%; other income approx. 18% of total profit), the 2027 industry step-down pattern, and share supply from the H-share offering and private placement unlock constitute a triple constraint over the next 12 months. Strategy: do not chase at current levels; odds turn favorable only on a pullback below the base-case lower bound of RMB 155. Key validation nodes: the January 2027 earnings preannouncement, NVIDIA's earnings on November 17, and positioning in memory test equipment orders.
What kind of opportunity is this. Genuine structural upcycle (global test equipment rising in both volume and price + domestic substitution target of the ~60% Japanese share) layered on top of earnings delivery already confirmed by the Q3 report — this is a growth-stock opportunity within a favorable cycle; but after a year of rally (+58.75% YTD, peak of RMB 374 followed by a 55% drawdown), the static valuation discount has disappeared, and the nature of the opportunity has shifted from "buying the upcycle" to "event-driven + odds management."
What is happening over the next 12 months (axis of change): First, the memory test equipment procurement season has substantively begun — CXMT (Changxin Memory Technologies) plans in September 2026 to invest RMB 5.0 billion in excess fundraising proceeds toward Phase II of its memory wafer back-end testing base; competitors Jingzhida and Yuexin have cumulatively won approx. RMB 4.4 billion in orders, while Changchuan has no public memory orders yet — positioning competition for the second growth curve is the largest source of expectation gaps. Second, the global ATE duopolists collectively raised guidance in July 2026 (Advantest raised FY2026 net profit guidance to +75.8%), indicating stronger upcycle persistence than earlier "step-down" fears; but Teradyne's intermittent compute orders have also been confirmed by management — the divergence in the 2027 growth path is precisely the core pricing variable at current prices. Third, the company's capital operations are intensive — the RMB 3.13 billion private placement has just been completed (issue price RMB 280.11/share, now under water approx. 40%), the H-share listing has entered the execution phase (expected issuance around mid-2027, dilution approx. 5–15%), and the placement shares unlock in February 2027 — supply-side events are concentrated in H1 2027.
Primary stock-price driver: The sustainability of downstream AI/memory capex simultaneously determines order growth and valuation multiples, making it the first variable in the current pricing framework; Teradyne/Advantest quarterly orders and guidance, NVIDIA's earnings, and the pace of CXMT/YMTC tenders are trackable leading indicators; the company's own leading indicators are contract liabilities (RMB 180 million at end-Q3, +79% QoQ) and goods in transit.
Verifiable expectation gap: The market anchor is sell-side consensus (2027E net profit approx. RMB 3.52 billion, median target price RMB 220, revised up 12.5% over the past 90 days); this report's own estimate for 2027E net profit is RMB 3.0–3.5 billion (midpoint approx. 8% below consensus, already incorporating the step-down pattern and H-share dilution) — the net divergence is small and bidirectional: the market has not yet paid for the memory ATE option (positive omission), nor fully priced in the H-share discount anchor and the unlock (negative omission). The exploitable point of the expectation gap lies in the timing of event delivery, not static valuation.
Validation and falsification: The January 2027 earnings preannouncement (>50% growth triggers mandatory disclosure) validates Q4 concentrated acceptance; downward revisions to Teradyne/Advantest guidance or book-to-bill falling below 1, the company's inventory impairment ratio exceeding 10%, and continued absence from memory tenders constitute falsification signals along three lines: industry cycle, financial statements, and market positioning.
The genuineness of the industry upcycle is cross-validated by the financials of both duopolists: Teradyne (2026Q3 revenue USD 1.306 billion, +70%, above the top of guidance) and Advantest (H1 2026 revenue +60.5%, operating profit +96.5%, full-year guidance raised). But two points of attribution need clarification: the widely circulated claim that "test time per AI chip is 27x that of a mobile SoC" has no traceable original source; the verifiable figures are that Blackwell final test time is approx. 4x Hopper's, and next-generation Rubin approx. 7x (Nomura, 2026-07) — the direction of the magnitude jump is true, but the multiple is exaggerated. The company's own stated primary drivers are digital testers (domestic substitution), analog-type testers and burn-in equipment; China's AI test content is lower than the global level, and the first-three-quarter 2026 growth includes M&A consolidation contributions (goodwill +39% vs. beginning of year, acquisitions such as PYXIS). The upcycle is real and the company benefits, but the "pure AI play" narrative framework overstates its direct linkage to NVIDIA capex.
Platform breadth is a genuine differentiator versus listed domestic peers: Huafeng Test only makes testers (mainly analog/mixed-signal), Kinghay only makes handlers; the company is the only domestic vendor mass-producing all four categories of back-end equipment, with tester–handler synergy sales penetrating the supply chains of JCET, Tongfu, Hua Tian, Silan, CR Micro, and SJ Semiconductor. But two contradictory figures must be called out: cross-validating the company's 2025 tester revenue of RMB 3.203 billion (including overseas; domestic approx. RMB 2.7 billion) against the approx. RMB 18 billion domestic market size yields an actual domestic share of approx. 15%, more than double the difference from the company's claimed 35% (the company's figure may include handlers or be counted by units; unverifiable); the "Japanese share 60%, substitution space approx. RMB 10.8 billion" figure is a broker-cited figure lacking independent third-party statistics. Meanwhile, Jingzhida has built a multi-line layout spanning memory testing + SoC testers and in October 2026 launched a SoC tester attacking the company's home turf; Yuexin Technology is anchored in memory ATE — the platform advantage is being eroded by domestic competitors' vertical expansion, and the testers' high 62–65% gross margin is itself the price umbrella attracting entrants.
Reverse-solving the current price: at a 2028 exit PE of 25–35x, implied 2028E net profit is RMB 3.1–4.3 billion, implying a 2025–2028 net profit CAGR of approx. 32–48% — i.e., "high growth delivered in 2026–2027, decelerating to approx. 15% in 2028." Against the RMB 1.765 billion already realized in the first three quarters and the consensus 2027E of RMB 3.52 billion, this requirement is not demanding; the pricing is reasonable rather than cheap. PEG is sensitive to the calculation basis: 2027E PE ÷ 2027E growth ≈ 0.70, 2026E PE ÷ 2027E growth ≈ 1.01 — not expensive, but by no means cheap, after growth adjustment. Base-case fair value RMB 155–195 (2027E net profit RMB 3.0–3.3 billion × 32–38x exit PE + net cash approx. RMB 2.87 billion), probability-weighted fair value approx. RMB 173, +2.9% vs. current price; the scenario probabilities of 25%/50%/25% are judgmental assignments, calibrated against the depth of the company's 2023 cycle (net profit -90%) and the 2026 guidance upgrades by both duopolists. Exit multiples are anchored to peers (A-share Huafeng/Kinghay currently at 50.8x/52.8x, Advantest TTM 34.6x, Teradyne forward approx. 44x, US equipment group NTM median approx. 38x), adjusted downward from peer current values for growth step-down — the company's own current multiple is not used as self-validation.
Deceleration in the year after an explosion is an industry pattern (Advantest +132.9% → +75.8%; Teradyne Q3 sequentially lower); the direction is established; but the industry's July 2026 upgrades indicate a milder decline than earlier fears — a "2027 hard landing" is not the base case. This report's own estimate for 2027E net profit is RMB 3.0–3.5 billion (+20–35%), approx. 8–15% below consensus of RMB 3.52 billion — the divergence is essentially a judgment difference over the sustainability of 2027 AI/memory capex and H-share dilution (not in consensus). To be noted: the company's domestic revenue is 84.55% of total; its driver structure differs from global AI SoC/HBM testing, and its domestic leading indicators are OSAT utilization rates and CXMT/YMTC tender pace, not a single NVIDIA chain; moreover, the company's own 2022–2023 cycle depth (revenue -31%, net profit -90%) far exceeded the global ATE downturn of the same period — the beta-amplification effect of domestic equipment stocks is the reason the bear case must be calibrated with the company's own history.
Inventory of RMB 6.180 billion is approx. 104% of first-three-quarter revenue, or approx. 78% of annualized revenue, while contract liabilities are only RMB 180 million (approx. 3% of inventory) — the advance-receipt buffer is extremely thin, and order validation depends almost entirely on shipment and acceptance timing. Profit "autonomy" is discounted: if 2025 capitalized R&D were expensed (15% tax rate), net profit would fall from RMB 1.331 billion to approx. RMB 1.049 billion, a reduction of approx. 21%; other income (software tax refunds + government subsidies) is 18% of total profit, and the company itself does not deem it fully sustainable; Q3 inventory surged YoY while the quarter's net impairment was nearly zero, with under-provisioning equivalent to approx. 6% of quarterly pre-tax profit. The other side must be fairly presented: first-three-quarter operating cash flow of RMB 1.039 billion (+1115% YoY), cash-to-revenue ratio approx. 93%, OCF/net profit recovering from 0.42 in 2025 to 0.59 — collections are genuinely improving. The issue is not that profits are fake, but that under a high-growth model, conversion of profit into cash is significantly diluted by inventory funding and policy-based income; the inventory impairment ratio in the 2026 annual report (2025 midpoint approx. 5.8%) is the next checkpoint.
Memory testers are the highest-value segment (approx. USD 1–3 million per unit, approx. 5–15x a general-purpose analog tester); the domestic localization rate of memory testers is only 8–10%, and CXMT's expansion (capacity already booked through end-2027) constitutes a genuine demand pool. But the reality: of the approx. RMB 4.4 billion in memory test orders already launched, all went to Jingzhida and Yuexin, and Changchuan has zero; CXMT Phase II's 37-month construction period means equipment procurement is concentrated after 2027 — even if Changchuan wins bids later, revenue would be realized in 2027H2–2028, and the April 2027 annual report window will most likely be unable to validate bulk revenue. If this option is exercised, it mainly benefits 2028 and beyond; this report does not include it in the base case. If Changchuan remains absent from memory tenders through 2026Q4–2027Q1, the "second curve" should be re-rated as "positioning behind," with share loss factored into the bear case.
| Metric (RMB 100 million) | FY2023 | FY2024 | FY2025 | 2026Q1–Q3 |
|---|---|---|---|---|
| Revenue | 17.75 | 36.42 | 52.92 | 59.42 |
| Revenue YoY | -31.1% | +105.2% | +45.3% | +57.3% |
| Net profit attributable to shareholders | 0.45 | 4.58 | 13.31 | 17.65 |
| Non-GAAP net profit attributable | -0.77 | 4.14 | 12.50 | 17.17 |
| Gross margin | — | 54.85% | 55.05% | 55.81% |
| Net profit margin (attributable) | 2.5% | 12.6% | 25.2% | 29.7% |
| Net operating cash flow | -7.44 | 6.26 (est.) | 5.62 | 10.39 |
| Free cash flow | -9.66 | 3.31 (est.) | ≈0 (est.) | 5.13 |
| Cash and equivalents (period-end) | 8.36 | 10.17 | 20.51 | 52.13 |
| Interest-bearing debt (period-end) | 13.03 | 14.83 | 21.73 | 28.82 |
| Debt-to-asset ratio | 50.9% | 49.8% | 51.0% | 46.5% |
| R&D investment (expensed basis 2026) | 7.88 (invested) | 10.25 (invested) | 12.68 (invested) | 9.42 (expensed) |
Note: Balance-sheet stock items are period-end figures; the latest period ends 2026-09-30. FY2024 operating cash flow and FY2024/FY2025 free cash flow are estimates based on comparative figures in the annual report cash flow statements (free cash flow = operating cash flow − cash paid for long-term assets); the 2025 difference between non-GAAP and attributable net profit was RMB 81 million (non-recurring items mainly government subsidies; note that software tax refunds and other "other income" fall within the non-GAAP basis and constitute policy-based recurring income).
Reasons for metric changes (YoY ≥ ±20% items, all per company disclosure): First-three-quarter revenue +57.25% due to "continued increase in sales demand" (Q3 report); operating cash flow +1114.71% due to "increased sales collections vs. the same period last year"; inventory +73.74% vs. beginning of year due to "inventory build-up alongside sales growth" and strategic stockpiling for supply-chain security and expected raw material price increases (investor relations record); cash +154.20% due to receipt of the RMB 3.13 billion private placement proceeds and increased collections; net profit attributable +103.92% due to revenue scale effects lifting net margin; other income +133.68% due to increased software tax refunds and government project subsidies; sharp rise in income tax expense due to higher profits; capital reserve +211.72% due to private placement premium; goodwill increase vs. beginning of year due to the PYXIS acquisition (2026H1 +47.71%); 2025 finance costs +1110.59% due to increased FX losses and interest expense.
Third-quarter standalone revenue was RMB 2,481 million (+53.9%), net profit attributable to parent RMB 801 million (+82.7%), quarterly gross margin 56.27%, and quarterly net margin attributable to parent 32.3% — all single-quarter records; cumulative non-recurring net profit for the first three quarters was RMB 1,717 million (+117.71%). Results landed near the midpoint of the guidance range disclosed on the evening of October 21 (net profit attributable to parent RMB 1,715–1,815 million), continuing to validate management's earlier statement that "existing orders support full-year growth." The balance sheet expanded in tandem: inventory of RMB 6,180 million (+73.74% vs. beginning of year), receivables of roughly RMB 2.7 billion (+35.8%, credit impairment losses of -RMB 41 million), and contract liabilities of RMB 180 million (+79.28%). Two points merit attention: first, quarterly net asset impairment losses were only RMB 518.5 thousand (vs. RMB 58.84 million in the same period last year), a markedly smaller provision despite inventory up +89% YoY — independent research estimates the under-provisioned portion at approximately 6.4% of quarterly pre-tax profit; second, the market is highly sensitive to "good news realized" — the stock fell four consecutive sessions before the guidance disclosure (cumulative roughly -8%) and kept falling after the Q3 report, closing down 5.95% at RMB 168.28 on October 30, the day global AI stocks slumped. This report does not have access to quarterly-level consensus data and makes no judgment on "beat or miss"; extrapolating from the typical Q4 acceptance-peak sequential pattern, 2026 full-year net profit attributable to parent is estimated at RMB 2.48–2.65 billion (Q4 standalone RMB 720–890 million), broadly in line with and 2–8% above the sell-side consensus of RMB 2.44 billion.
Business model: A build-to-order plus inventory-based pre-production specialized equipment maker, primarily direct sales; revenue is one-time equipment sales with no subscription or service revenue breakdown, making revenue non-recurring. Core components (high-speed FPGA/ADC-DAC, etc.) are partially dependent on imports from the US and Japan; R&D-intensive (2025 R&D spend of RMB 1,268 million, 24% of revenue). Weak pricing power: blended gross margin flat for three years (54.85% → 55.05% → 55.81%); management stated at the earnings briefing that "product prices are below comparable foreign models" — competing on value-for-market-share rather than price increases, consistent with the import-substitution stage strategy but also capping gross margin upside.
Cash content of earnings: OCF/net profit attributable to parent was -16.5 in 2023 (distorted net profit base), 1.36 in 2024, 0.42 in 2025, and 0.59 for 9M26; FCF/net profit attributable to parent was 0.72 in 2024, near zero in 2025 (estimated: free cash flow = OCF of RMB 562 million − capex of RMB 555 million, an almost exact offset), and 0.29 for 9M26. Long-term cash conversion is below the 0.8 warning threshold, mainly due to working capital advances for capacity buildup and inventory stocking (about RMB 0.55 of net advance per RMB 1 of incremental revenue in 2025) and expansionary capex — not runaway receivables (receivables growth of 35.8% below revenue growth of 57.25%). A cash flow turnaround is underway in 2026: 9M26 OCF of RMB 1,039 million with a cash collection ratio of roughly 93%.
Recurring earnings test: Non-recurring net profit of RMB 1,250 million in 2025 differs from net profit attributable to parent by only 6%, but structurally "other income" of RMB 221 million (software VAT refunds plus subsidies, 16.6% of total profit) is included within the non-recurring figure — policy-driven income rather than market-based profit. If R&D capitalization (RMB 332 million) is also reversed, 2025 "core operating profit" would be roughly RMB 1.05 billion, about 21% lower than reported. The current 48.6x PE-TTM corresponds to roughly 62x on this adjusted basis.
Return on capital: Estimated ROIC of about 9.1% in 2024 and about 17.9% in 2025 — crossing the 15% moat line in 2025 — but the rise in capital returns relies on profit elasticity rather than efficiency of the existing capital base, and the 2026 private placement enlarged the capital base by RMB 3.1 billion, which will dilute and test ROIC.
Capex quality: CapEx/depreciation was 2.61 in 2024 and 4.08 in 2025, reflecting expansionary investment in the Hangzhou high-end intelligent manufacturing base (commissioned May 2025, RMB 1.23 billion capitalized that year) and Neijiang Phase II; the company does not disclose a maintenance/growth split, so maintenance-level investment cannot be determined. Capacity utilization: 96.35% in 2024 → 82.79% in 2025 → 87.30% in 2026H1; the new base is ramping and not yet saturated.
Red flags: Top-five customer concentration of 57.66%, largest customer 22.79% (2025), concentrated among leading OSAT players; cumulative dividends of about RMB 368 million since listing vs. cumulative refinancing of over RMB 3.4 billion (RMB 277 million supporting fundraising in 2023 + RMB 3.13 billion private placement in 2026) — growth prioritized over shareholder cash returns (2025 payout ratio of 4.8%).
Consistency of words and deeds: pragmatic and mostly delivers, but with a record of execution delays. Delivered: the October 2026 earnings guidance range (RMB 1,715–1,815 million) was narrow and the actual figure of RMB 1,765 million landed near the midpoint — high forecast precision; the May 2026 statement that "existing orders support full-year growth" is being validated quarter by quarter. Not fully delivered: the 2023 placement-funded "turret handler development and industrialization project" had reached only 56.07% of planned investment as of 2026H1, with the production-ready date pushed from September 2027 to September 30, 2028; the high-end intelligent manufacturing base commissioned in May 2025 with projected revenue of RMB 5 billion is currently at 82.79% capacity utilization (company characterization: "not yet saturated") — partially delivered.
Shareholder friendliness: neutral to weak. RMB 1 per 10 shares for three consecutive years (2025 payout ratio of only 4.8%; new interim dividend of RMB 63 million in 2026); no record of executed buybacks (on October 15, 2026 the controlling shareholder proposed a buyback capped at RMB 100 million, about 0.06% of market cap — largely symbolic, pending plan implementation); on the other hand, persistent equity financing: the August 2026 private placement of RMB 3.13 billion (RMB 280.11/share) was followed just one month later by an announced plan for an H-share listing, which media questioned as "frequent cash-raising" — the growth-stage priority of funding R&D and capacity is clear, with dilution borne by secondary-market shareholders.
Risk signals: Controlling shareholder Zhao Yi holds 21.93% (about 23.07% including parties acting in concert), with no pledge/freeze risk (pledge ratio 3.56%); however, concert party Changchuan Investment has cumulatively reduced about 30.198 million shares (about 4.7% of total share capital) since August 2025, cashing out about RMB 3.045 billion; its 12-month no-sale commitment from April 2026 expires around April 2027; director and deputy general manager Zhong Fenghao reduced 971,500 shares in January 2026 (average price RMB 128.66); one director departed in August 2026. No material related-party transactions disclosed.
| Product Line | 2025 Revenue Share | 2025 Gross Margin | 2025 YoY | 2026H1 Share / Gross Margin / YoY | Business Logic |
|---|---|---|---|---|---|
| Testers | 60.53% | 62.25% (-4.36pp) | +55.29% | 54.07% / 64.94% / +49.74% | High-power / mixed-signal / digital SoC / burn-in testers; highest value and margin, main force of import substitution |
| Handlers | 29.64% | 41.34% (+4.99pp) | +31.76% | 33.46% / 41.44% / +63.30% | Gravity / translational / turret (EXIS) types; mechanical in nature, crowded competitive field |
| Others (automation + AOI + probers) | 9.83% | 52.09% | +33.86% | 12.46% / 52.15% / +107.46% | AOI (STI) + vision + automation + tri-temp probers; fastest-growing new category |
Testers are the profit engine: Estimated by revenue share × gross margin, testers contribute about 68% of gross profit (handlers about 22%, others about 9%) — not a direct mapping of revenue share; testers deliver nearly 70% of gross profit on 60% of revenue. The reason for the 21-percentage-point gross margin gap (62.25% vs. 41.34%): testers are the technology-barrier segment (high-speed digital channels, timing precision, test program ecosystems), while handlers are precision machinery plus temperature control, with ample domestic competition from players like Kinghayton — the two lines are fundamentally different businesses: testers determine profit elasticity, handlers determine customer coverage and order stickiness. Key tracking point: tester gross margin, after falling 4.36pp in 2025, rebounded to 64.94% in 2026H1; if memory/SoC competition intensifies into a price war, this line item is the first signal.
Leading indicators for order-based equipment (detailed disclosure): Contract liabilities: RMB 10 million at end-2023 → RMB 32 million at end-2024 → RMB 100 million at end-2025 → RMB 180 million at end-2026Q3 (+79.28%); advances are expanding year after year but the absolute amount is only 3% of 9M revenue, and the company does not disclose total backlog; goods in transit (shipped but not yet accepted): RMB 577 million at end-2024 → RMB 849 million at end-2025 → RMB 1,232 million at end-2026H1 — a leading indicator of the Q4 concentrated revenue recognition pattern.
Accounting red flags (by severity):
Cross-period consistency: OCF/net profit attributable to parent (-16.5 → 1.36 → 0.42 → 0.59) swings sharply but is consistent with management's period-by-period attributions (revenue decline → improved collections → stocking advances → renewed collection improvement); inventory/revenue ratio (121.6% → 61.3% → 67.2% → 104%) has risen for two consecutive years — the company's explanation matches order growth, directionally consistent but dependent on the cycle continuing; top-five customer concentration (51.34% → 62.07% → 57.66%) jumped in 2024 and remains elevated — the company has not explained this; capacity utilization (62.78% → 96.35% → 82.79% → 87.30%) swings widely in line with the expansion pace — the company has not formally explained this. Overall judgment: no evidence of fabricated revenue or obvious manipulation, but the combination of "high growth + high inventory + high capitalization + high policy-driven income" makes earnings quality highly sensitive to a cyclical reversal — in a downturn, the reported profit's elasticity will exceed revenue's.
Current market data (close of 2026-10-30): Share price RMB 168.28, market cap RMB 108.363 billion, total shares 643.94 million. PE-TTM 48.6x (0th percentile over the past 1 year, 5th percentile over 5 years — a mirror of the surging denominator; percentiles are for downside reference only); static PE 82.0x; PB 11.64x (47th percentile over 5 years, against 9M26 ROE of 25.0% / annualized about 33% — the PB-ROE combination is not outrageous); PS-TTM 14.5x. Forward: 2026E PE 42.2–44.4x, 2027E 30.8–33.3x; PEG roughly 0.70 (2027 basis) to 1.01 (2026 basis).
| Company | PE-TTM | 2026 Growth (Net Profit / Revenue) | ROE | Positioning |
|---|---|---|---|---|
| Changchuan Technology | 48.6 | Net profit +104% (9M26) | 9M26 25.0% | Full-category platform, largest domestic scale |
| Accotest | 50.8 | Net profit +67.9% (9M26) | 9M26 11.1% | Analog/mixed-signal tester leader, narrow product range |
| Kinghayton | 52.8 | Net profit +159% (9M26) | 9M26 18.1% | Handlers only, about 13% of Changchuan's scale |
| Advantest | 34.6 | FY2026 guidance net profit +75.8% | Net margin 33.3% | 65% global share in SoC/memory testers |
| Teradyne | 44.0 | Q3 revenue +70% | — | Global top two, AI about 70% of business |
(Peer multiples are a 2026-10-31 snapshot; the three A-share names are based on exchange quotes and financial reports, the two overseas names on public market snapshots; A-shares carry a systematic market premium versus Japanese/US leaders, so benchmarking should focus on relative positioning rather than absolute values.)
Market-implied expectations: Back-solving the current price at a 25–35x exit PE on 2028 implies 2028E net profit attributable to parent of RMB 3.1–4.3 billion, a 2025–2028 CAGR of 32–48% — i.e., the market demands "high growth delivered through 2026–2027, decelerating to about 15% in 2028." Reality anchors: 9M26 already realized RMB 1,765 million; full-year self-estimate RMB 2.48–2.65 billion (consensus RMB 2.44 billion); 2027 consensus RMB 3.52 billion; this report's own estimate RMB 3.0–3.5 billion. In one sentence: what the current price demands is roughly what the company is already delivering — no premium paid for the memory option, no discount for dilution — fairly priced, not cheap.
Three layers of value: Asset value (floor) about RMB 14.5/share (book net assets basis; inventory of RMB 6.18 billion is 66% of net assets with heavy liquidation discounts; the replacement value of the technology platform and customer qualifications far exceeds book value but is not quantifiable); EPV no-growth value about RMB 44.7/share (normalized FCFF of RMB 3.82/share ÷ WACC 9.5% + net cash of RMB 4.46/share; normalization assumes 2026 profit margins mean-revert toward 27% and zero working capital advances in steady state); about 73% of the current price is supported by growth options (this report's own calculation). A high growth share does not by itself constitute an overvaluation judgment — the turning point's authenticity is corroborated by the two giants' earnings and SEMI data; but it frames the risk structure: once the 2027 capex narrative wavers, the current price has no no-growth-value floor, and the downside goes straight to the left tail of the scenario distribution.
Three scenarios and odds:
| Scenario | Probability | Fair Range | vs. Current Price | Core Assumptions |
|---|---|---|---|---|
| Bear | 25% | RMB 65–85 | -52% to -61% (midpoint -55%) | AI/memory capex digestion phase transmits: 2027 orders decline, inventory impairment 5–10%, 2027 net profit falls back to RMB 1.6–2.0 billion × 25x |
| Base | 50% | RMB 155–195 | -7.9% to +15.9% (midpoint +4.0%) | 2027 net profit RMB 3.0–3.3 billion (+20–35%, incorporating deceleration and dilution) × 32–38x + net cash of RMB 2.87 billion |
| Bull | 25% | RMB 240–295 | +42.6% to +75.3% (midpoint +59%) | Capex does not decelerate: 2027 net profit RMB 3.8–4.2 billion (consensus upgrades) × 40–45x; high-end SoC / overseas breakthroughs |
Probability-weighted fair value is about RMB 173 (+2.9%). The bear-case anchor: Accotest's 3-year low PE of 27.9x, marked down further, calibrated against the company's own 2023 cyclical depth (net profit -90%); external bearish views (Teradyne compute order pauses, independent research questioning earnings quality) are directionally consistent but provide no price targets — the bear case here is an independent stress assumption. The base-case exit multiple of 32–38x is anchored to the current peer range and marked down for decelerating growth, not to the company's own current multiple; the bull case does not depend on the memory option (whose payoff mainly lies beyond 2028).
Three-Way Comparison: Own Forecasts vs. Management/Consensus:
| Basis | FY2026 Revenue / Net Profit | FY2027 Revenue / Net Profit |
|---|---|---|
| This report's estimate | RMB 8.6–9.0 bn / RMB 2.48–2.65 bn | RMB 10.5–12.0 bn / RMB 3.0–3.5 bn |
| Sell-side consensus (2026-10-30) | — / about RMB 2.44 bn | — / about RMB 3.52 bn |
| Management | "Existing orders support full-year growth" (no quantification); guidance already delivered | Not disclosed |
Conclusion: Fairly priced (fair). Target price RMB 155–195 (base-case fair value), margin of safety about -7.9% — quality (platform leader, rising ROIC, genuine upcycle) coexists with a fair price; the expected return from buying at the current price is near zero, with a risk-reward profile that is roughly symmetric within the base range.
Market size. The global semiconductor test equipment (back-end ATE and peripherals) market is approximately US$11.7 billion in 2025 (+55.3%); SEMI's mid-year forecast (July 2026) projects US$15.3 billion in 2026 (+31%) and US$20.8 billion in 2028 (2025–2028 CAGR of ~21%) — the fastest-growing segment among all semiconductor equipment categories (over the same period, front-end WFE grew +11% in 2025 and assembly & packaging equipment +20.8%). Within this, SoC testers grew from US$3.3 billion in 2023 to US$6.9 billion in 2025 and are estimated at US$9.1 billion in 2026E (Advantest basis, CAGR ~40%); memory testers are estimated at ~US$2.45 billion in 2026E. Test equipment accounts for roughly 9% of the total global semiconductor equipment market. China market: the domestic tester market is approximately RMB 18 billion (Dongwu citing Advantest; no independent third-party statistics available), with Japanese players holding ~60% — i.e., a domestic substitution target of roughly RMB 10.8 billion.
Quantified chain of the demand inflection (the most important variable in this industry today). Drivers: AI/HPC accelerator volume ramp combined with an order-of-magnitude increase in test intensity per chip — verifiable figures: Blackwell final test time is about 4x that of Hopper, Rubin about 7x (Nomura, 2026-07); Chiplet architectures require KGD full inspection of each die, and HBM stacking adds new KGSD/TSV/CoW test steps (the widely circulated "27x" figure lacks an original source — the magnitude is exaggerated but the direction is real). Penetration: SoC testers' share of the global tester market rose from 23% in 2018 to 63% in 2025 (SEMI); AI chips account for ~40% of overseas SoC test demand in 2025, versus only ~17% in China (Dongwu estimate) — domestic AI test penetration is at the start of its ramp, with the greatest elasticity but also the greatest uncertainty. Share: global high-end supply is highly concentrated in Advantest + Teradyne (combined ~80%, 90%+ in high-end); Advantest's SoC share rose from 56% to 66% within one year. Among domestic players, Changchuan held ~10% of the overall domestic test equipment market in 2025 (company figure, target 30%+), with a tester share of ~15% cross-verified by revenue. Both ends of this chain have hard data (AI server shipments, the two giants' earnings), while the middle link (the company's AI-related revenue share) is undisclosed — this is precisely why attribution in C1 warrants caution.
Value chain and value distribution. Upstream: high-speed FPGA/ADC-DAC, relays, probe cards, precision motion and temperature-control platforms; some high-end components depend on US/Japan imports (potential transmission points of export controls). Midstream: four equipment categories — testers (highest value and gross margin; company tester gross margin 62–65%), handlers (~41%), wafer probers, and AOI. Downstream: OSAT (JCET, Tongfu, Huatian, ASE) + IDM (Silan Micro, CR Micro) + foundry CP testing + third-party test houses (Weitest, etc.); final test costs are absorbed across the chip value chain (third-hand figure: NVIDIA GB200 per-unit packaging & test cost ~US$700, of which test ~US$180). The company sits in the core midstream segment, with moderate-to-weak bargaining power over large downstream customers (top five account for 57.66%), while holding substitution options vis-à-vis suppliers amid ongoing domestication. Packaging & test capex is flowing toward the test segment: testers accounted for 53.5% of SHJM's equipment purchases in 2025H1; test equipment represents over 80% of Weitest's RMB 2 billion convertible bond project spending; and of Tongfu's RMB 4.22 billion private placement (completed August 2026), ~RMB 3.18 billion is for equipment purchases — downstream financing and capacity expansion translate directly into a pool of test equipment orders.
Supply-demand and competitive landscape. Four demand engines: AI/HPC (volume-price double boost), memory recovery (HBM adds new test steps; roughly half of Advantest's memory test business is HBM-related), analog recovery, and substitution driven by domestic computing power and export controls. Supply side: bottlenecks in high-end SoC/memory tester supply (order-of-magnitude expansion in AI test hours squeezes capacity), while intensified homogeneous competition among domestic players in mid/low-end segments concentrates price-war risk in analog testers and conventional handlers. Concentration: global CR2 ~80%; domestically, multiple players coexist — Changchuan (platform-based), Huafeng (analog testers, 8,000+ cumulative global installs), Jinhaitong (translation-type handlers), Liandong Technology, Kingsemi, and Yuexin. Entry barriers: 18–36-month customer qualification cycles at leading customers, extremely high test program library migration costs, and hardware barriers in high-speed channel counts and timing precision — but these barriers protect the high end, while the mid/low end is being rapidly filled by domestic capacity (Kingsemi had accumulated ~RMB 2.89 billion in orders by 2026 and Yuexin over RMB 1.5 billion, totaling ~RMB 4.4 billion, all in memory testing).
Cycle and regulation. The industry is in the third year of an upcycle (2024 recovery → 2025 explosion → 2026 continuation), layered with structural AI-driven increments. Marginal signals are two-sided: in July 2026 the two giants collectively raised guidance vs. Teradyne's intermittent compute orders and Q3 guidance declining sequentially — a flattening slope on a high base is consensus; the magnitude is the point of contention. Regulation is a net positive but carries two-way tail risk: US restrictions on China (HBM and advanced equipment limits; CXMT listed as a "Chinese military company" with entity list decision not yet effective) reduce accessibility of overseas high-end testers, making the Japanese 60% share a substitution target; the reverse risks are that restrictions on domestic AI chips themselves suppress high-end demand release, and that a US-China thaw would weaken the substitution narrative. Since July 2023, Japan has required export licenses for 23 categories of semiconductor equipment (including test equipment), reinforcing domestic "de-Japanization" procurement tendencies; the Big Fund III and equipment domestication policies continue to add support.
The company's industry position. The absolute leader in domestic back-end test equipment (2025 revenue RMB 5.292 billion, roughly 3.9x Huafeng's and 7.6x Jinhaitong's), with share trending upward (global share ~3% in 2021 → ~10% of the overall domestic market). Moat sources = product breadth (the only domestic player with all four categories in mass production) + customer lock-in (leading OSAT and IDM supply chains) + M&A channels (STI/EXIS/PYXIS bringing overseas customers such as Texas Instruments, Amkor, Samsung, and ASE, plus Malaysian capacity). Weaknesses: a 1–2 generation technology gap versus Advantest/Teradyne in high-end digital/memory testers; memory ATE still in introduction (not yet in mass production); blended gross margin ~55%, below Huafeng's 74% (dragged by the handler mix). Share figures must be presented side by side: the company claims ~35% domestic tester market share (May 2026 earnings briefing), but cross-verification using 2025 tester revenue of RMB 3.203 billion (of which ~RMB 2.7 billion domestic) ÷ domestic market of ~RMB 18 billion yields ~15% — a gap of more than twofold between the two figures. The company's figure may include unit counts or handler statistics; this report adopts the revenue cross-verified figure and flags the uncertainty.
As an order-driven special-purpose equipment maker, the company's revenue recognition chain runs "order → production/inventory build → shipment (goods in transit) → customer acceptance → revenue recognition." This model defines three trackable leading indicators and two structural features:
Leading indicators: ① Contract liabilities (advance receipts): RMB 10 million at end-2023 → RMB 100 million at end-2025 → RMB 180 million at end-2026Q3 — sustained expansion but only 3% of first-three-quarter revenue, indicating weak advance-payment requirements and low order lock-in. ② Goods in transit (shipped, pending acceptance): RMB 577 million at end-2024 → RMB 1.232 billion at end-2026H1 — the most direct revenue recognition reservoir. ③ Inventory structure (raw materials/WIP/goods in transit): raw materials doubling within a year reflects order expectations rather than signed orders; if the cycle reverses, this line item is the first site of impairment.
Structural features: ① Seasonal pulse in revenue recognition — 2025Q4 net profit attributable of RMB 466 million was 35% of the full year; per the company, "heavy early shipments with acceptance concentrated in Q4." This makes the earnings preannouncement around the annual report the single most important disclosure of the year, and amplifies signal noise around single-quarter misses (delayed acceptance ≠ lost orders, but the market struggles to distinguish). ② Order visibility of only about six months (company figure) — significantly shorter than front-end equipment makers (typically 1–2 years), meaning the company's "downside buffer depth" is thin and the lag from industry inflection to financial statements is shorter. Total backlog is undisclosed (the market-circulated ~RMB 1.8 billion at end-2025 is third-hand and unverifiable). Tracking advice: read contract liabilities quarter-over-quarter, goods-in-transit balance, and inventory write-down provisions together as the dashboard of company-level order momentum; at the industry level, use OSAT capex cash growth and CXMT/YMTC tender announcements as benchmarks.
Overall: Neutral, confidence 0.55, horizon 6–12 months. Changchuan Technology is China's most complete beneficiary of the current semiconductor test equipment cycle: platform-based products, genuinely delivered profitability (first-three-quarters attributable profit +104%), rising ROIC (~18%), and improving cash flow. But the current price of RMB 168.28 already fairly prices the base-case growth path (base-case fair value RMB 155–195, weighted fair value ~RMB 173, margin of safety -7.9%); odds are roughly symmetric with a deeper downside tail (bear-case midpoint -55% vs. bull-case midpoint +59%; the left-skewed distribution is determined by RMB 6.18 billion of inventory and the 2027 base-deceleration pattern). Scoring quality and price separately: excellent quality, fairly priced — this is neither a buy rating nor a short candidate (cycle and share trends are still rising; sell-side estimates are still being revised upward).
Strategy implications: Holders should hold, using RMB 155 (base-case floor) and RMB 130 (bear-case activation line) as tiered reassessment anchors. Non-holders should wait for one of two entry signals: a price pullback below RMB 155 (odds turn favorable), or confirmation of positioning in memory tester/high-end SoC orders (fundamental upgrade). Three events in the first half of 2027 will set direction: the January earnings preannouncement (degree of Q4 acceptance delivery), the February 12 private placement unlock and H-share issuance pace (share supply), and Teradyne/Advantest spring guidance (setting the 2027 cycle tone).
Risk and catalyst calendar:
Upside catalysts: the 2026 annual results preannouncement delivering the Q4 peak season (by January 31, 2027); NVIDIA earnings and guidance from the two giants confirming the upcycle (from 2026-11-17); progress on H-share listing milestones (filing expected 2026Q4–2027Q1, issuance 2027Q2–Q3); order breakthroughs in memory testers or the D9000 high-end SoC; equipment tenders from downstream players such as Tongfu/Weitest after financing lands; and implementation of the buyback proposed by the actual controller. Downside triggers: Teradyne/Advantest guidance cuts or book-to-bill below 1 (AI digestion phase confirmed — industry line); 2026 annual inventory write-down ratio exceeding 10% (inventory risk realized — statement line); R&D capitalization rate sustained above 25% with other income over 20% of total (profit quality deteriorating); continued absence from CXMT/YMTC memory tenders while competitors win large orders (second curve falsified — positioning line); H-share issuance discount exceeding 40% or size exceeding 10% of share capital (valuation anchor shifting down); block-trade discounts around the unlock and the expiry in April 2027 of Changchuan Investment's no-reduction pledge (chip supply line); export control tails (upstream component cutoff or CXMT entity list taking effect). Most of these conditions are already on the monitoring list; any trigger prompts immediate reassessment.
This report is based on the closing price of October 30, 2026 (RMB 168.28) and public information as of November 1, 2026; all cited data are sourced, and the three scenarios and forecasts are analyst judgments and do not constitute investment advice.